Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Researchers at Dana-Farber Cancer Institute were awarded a $900,000 grant from the Ovarian Cancer Research Fund (OCRF) to test new combinations of targeted drugs against the disease.
Ursula Matulonis, MD, the director of the Gynecological Cancer Treatment Center in the Susan F. Smith Center for Women’s Cancers at Dana-Farber is the principal investigator of the Program Project Development Grant from OCRF. This grant helped mark OCRF’s 20th anniversary for which foundation awarded an unprecedented $6.9 million in research and program grants to support gynecologic cancer patients.
“The ultimate goal of this project is to quickly bring laboratory-tested and verified novel drug combinations into ovarian cancer clinical trials,” says Matulonis.
She notes that treatment advances in ovarian cancer have reached a plateau. “Newer agents that target ovarian cancer genetic abnormalities have shown some efficacy as single agents, but cancer cells eventually figure out ways to grow despite the drug,” says Matulonis. Because of that, Matulonis and her team will explore a number of strategies that combine drugs that simultaneously target several abnormal biologic pathways in ovarian cancer cells. In one project, researchers will test the effectiveness of a PARP inhibitor and another targeted therapy in blocking the abnormal PI3-kinase signaling pathway in ovarian tumors.
A second project will combine two drugs – a heat shock protein (HSP) inhibitor and a PARP inhibitor – aimed at preventing damaged ovarian cancer cells from repairing themselves. The third project will use a technique called BH3 profiling, which measures how close cancer cells are to destroying themselves, to evaluate targeted drug combinations.
Other investigators funded by the grant are Gerburg Wulf, MD, PhD, of Beth Israel-Deaconess Medical Center; and Dana-Farber researchers Panagiotis Konstantinopoulos, MD, PhD; Anthony Letai, MD, PhD; Joyce Liu, MD, MPH, and William Barry, PhD.